Advances in GPCR-Targeted PET Radiotracer Patents (2020-2025).

Area of Science:

• Molecular Imaging
• Radiochemistry
• Pharmacology

Background:

• Positron emission tomography (PET) enables non-invasive in vivo imaging of biological processes.
• G protein-coupled receptors (GPCRs) are key targets for PET radiotracers due to their disease relevance.
• Radiotracers must exhibit high affinity and selectivity for their molecular targets.

Purpose of the Study:

• To review patents (2020-2025) on GPCR-targeted PET radiotracers.
• To analyze design strategies, radionuclide choices, and translational applications.
• To cover oncology, CNS disorders, and inflammatory diseases.

Main Methods:

• Patent literature analysis (2020-2025).
• Focus on GPCR-targeted PET radiotracers.
• Categorization by disease area and design approach.

Main Results:

• Most tracers adapt existing ligands for imaging.
• Oncology patents favor peptide/metal-chelator platforms for theranostics.
• CNS tracers use small molecules optimized for blood-brain barrier penetration.
• Emerging strategies target GPCR signaling states, not just binding sites.

Conclusions:

• GPCR-targeted PET tracers are established diagnostic tools.
• Patent trends show expanding clinical utility and translational research applications.
• Theranostic strategies incorporating GPCR tracers are developing across diseases.